Ferraris V A, Ferraris S P, Singh A
Department of Cardiovascular Service, Marshall University, Huntington, WV, USA.
J Thorac Cardiovasc Surg. 1998 Mar;115(3):593-602; discussion 602-3. doi: 10.1016/S0022-5223(98)70324-1.
Because of concern about increasing health care costs, we undertook a study to find patient risk factors associated with increased hospital costs and to evaluate the relationship between increased cost and in-hospital mortality and serious morbidity.
More than 100 patient variables were screened in 1221 patients undergoing cardiac procedures. Simultaneously, patient hospital costs were computed from the cost-to-charge ratio. Univariate and multivariate statistics were used to explore the relationship between hospital cost and patient outcomes, including operative death, in-hospital morbidity, and length of stay.
The greatest costs were for 31 patients who did not survive operation ($74,466, 95% confidence interval $27,102 to $198,025), greater than the costs for 120 patients who had serious, nonfatal morbidity ($60,335, 95% confidence interval $28,381 to $130,897, p = 0.02) and those for 1070 patients who survived operation without complication ($31,459, 95% confidence interval $21,944 to $49,849, p = 0.001). Breakdown of the components of hospital costs in fatalities and in cases with nonfatal complications revealed that the greatest contributions were in anesthesia and operating room costs. Significant (by stepwise linear regression analysis) independent risks for increased hospital cost were as follows (in order of decreasing importance): (1) preoperative congestive heart failure, (2) serum creatinine level greater than 2.5 mg/dl, (3) New York state predicted mortality risk, (4), type of operation (coronary artery bypass grafting, valve, valve plus coronary artery bypass grafting, or other), (5) preoperative hematocrit, (6) need for reoperative procedure, (7) operative priority, and (8) sex. These risks were different than those for in-hospitality death or increased length of stay. Hospital cost correlated with length of stay (r = 0.63, p < 0.001), but there were many outliers at the high end of the hospital cost spectrum.
We conclude that operative death is the most costly outcome; length of stay is an unreliable indicator of hospital cost, especially at the high end of the cost spectrum; risks of increased hospital cost are different than those for perioperative mortality or increased length of stay; and ventricular dysfunction in elderly patients undergoing urgent operations for other than coronary disease is associated with increased cost. Certain patient factors, such as preoperative anemia and congestive heart failure, are amenable to preoperative intervention to reduce costs, and a high-risk patient profile can serve as a target for cost-reduction strategies.
由于对医疗保健成本不断增加的担忧,我们开展了一项研究,以找出与住院成本增加相关的患者风险因素,并评估成本增加与住院死亡率和严重发病率之间的关系。
对1221例接受心脏手术的患者的100多个患者变量进行了筛查。同时,根据成本收费比计算患者的住院费用。采用单变量和多变量统计方法探讨住院费用与患者预后之间的关系,包括手术死亡、住院发病率和住院时间。
31例手术未存活患者的费用最高(74,466美元,95%置信区间27,102美元至198,025美元),高于120例发生严重非致命性疾病患者的费用(60,335美元,95%置信区间28,381美元至130,897美元,p = 0.02)以及1070例手术存活且无并发症患者的费用(31,459美元,95%置信区间21,944美元至49,849美元,p = 0.001)。对死亡患者和非致命并发症患者的住院费用组成部分进行分解后发现,最大的贡献在于麻醉和手术室费用。(通过逐步线性回归分析)住院费用增加的显著独立风险如下(按重要性降序排列):(1)术前充血性心力衰竭,(2)血清肌酐水平大于2.5mg/dl,(3)纽约州预测的死亡风险,(4)手术类型(冠状动脉搭桥术、瓣膜手术、瓣膜加冠状动脉搭桥术或其他),(5)术前血细胞比容,(6)再次手术的需求,(7)手术优先级,以及(8)性别。这些风险与住院死亡或住院时间延长的风险不同。住院费用与住院时间相关(r = 0.63,p < 0.001),但在住院费用范围的高端有许多离群值。
我们得出结论,手术死亡是最昂贵的结局;住院时间是住院费用的不可靠指标,尤其是在费用范围的高端;住院费用增加的风险与围手术期死亡率或住院时间延长的风险不同;老年患者因非冠状动脉疾病接受紧急手术时的心室功能障碍与费用增加相关。某些患者因素,如术前贫血和充血性心力衰竭,适合术前干预以降低成本,高危患者概况可作为成本降低策略的目标。